Item 5.07. Submission of Matters to a Vote of Security Holders.
Pliant Therapeutics, Inc. (the "Company") held its Annual Meeting of
Stockholders (the "Annual Meeting") on June 29, 2021. As of April 30, 2021, the
record date for the Annual Meeting, there were 35,875,918 shares of the
Company's common stock outstanding and entitled to vote at the Annual Meeting.
The Company's stockholders voted on the following matters, which are described
in detail in the Company's Definitive Proxy Statement filed with the U.S.
Securities and Exchange Commission on April 30, 2021: (i) to elect Hoyoung Huh,
M.D., Ph.D., Neil Exter, MBA, and David Pyott, MA, MBA, as Class I directors of
the Company to serve for a three-year term expiring at the Company's 2024 Annual
Meeting of Stockholders and until his successor has been elected and qualified
("Proposal 1"), and (ii) to ratify the appointment of Deloitte & Touche LLP as
the Company's independent registered public accounting firm for its fiscal year
ending December 31, 2021 ("Proposal 2").
Proposal 1: The Company's stockholders approved the election of the
aforementioned Class I directors recommended for election at the Annual Meeting.
The Company's stockholders voted for the Class I directors as follows:
Nominee For Withhold
Hoyoung Huh, M.D., Ph.D. 13,651,371 5,881,007
Neil Exter, MBA 13,663,543 5,868,835
David Pyott, MA, MBA 19,517,150 15,228
The broker non-votes for this Proposal 1 totaled
The broker non-votes for this Proposal 1 totaled 4,874,323 shares of common
stock.
Proposal 2: The Company's stockholders ratified the selection of Deloitte &
Touche LLP as the Company's independent registered public accounting firm. The
votes cast at the Annual Meeting were as follows:
For Against Abstain
24,376,650 28,928 1,123
No other matters were submitted to or voted on by the Company's stockholders at
the Annual Meeting.
1
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses